Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Updates 2024 Growth Outlook
Summary
Jazz Pharmaceuticals plc provided an update on its 2024 growth outlook during the J.P. Morgan Healthcare Conference on January 8, 2024. The company expects to meet its previously announced total, neuroscience, and oncology revenue guidance for the year ended December 31, 2023. Jazz anticipates double-digit percentage revenue growth from its key growth drivers: Xywav, Epidiolex, and Rylaze in 2024. The company also expects high-sodium oxybate authorized generic royalty revenue to exceed $200 million in 2024.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement